– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500

Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer f

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the

–  Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructi

Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outp

— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in r

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX)

Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy

BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperfo

Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial i

Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D

Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart

HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates Edgewise Therapeutics (NASDAQ:EWT

Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart

– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –– Consi

– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Cons

Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of

BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company

EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture d

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperfo

Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and r

Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy

 The transaction meaningfully strengthens Edgewise's balance sheet, providing enhanced financial

— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $

BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading m

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.46) per share which beat the an

–  Announced positive long-term sevasemten data demonstrating sustained functional stabilization in

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc

BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"

ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Edgewise Therapeutics (NASDAQ: EWTX - Get Free R

Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shares hit a new 52-week high on Tuesda

Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) have been given an average ra

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for